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Summary. Low-risk prostate cancer patients enrolled in active surveillance (AS) programs commonly undergo biopsies on
a frequent basis for examination of cancer progression. AS programs employ a ﬁxed schedule of biopsies for all patients.
Such ﬁxed and frequent schedules may schedule unnecessary biopsies. Since biopsies are burdensome, patients do not always
comply with the schedule, which increases the risk of delayed detection of cancer progression. Motivated by the world’s
largest AS program, Prostate Cancer Research International Active Surveillance (PRIAS), we present personalized schedules
for biopsies to counter these problems. Using joint models for time-to-event and longitudinal data, our methods combine
information from historical prostate-speciﬁc antigen levels and repeat biopsy results of a patient, to schedule the next biopsy.
We also present methods to compare personalized schedules with existing biopsy schedules.
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1. Introduction
Prostate cancer (PCa) is the second most frequently diag-
nosed cancer (14% of all cancers) in males worldwide (Torre
et al., 2015). The increase in diagnosis of low-grade PCa has
been attributed to increase in life expectancy and increase in
the number of screening programs (Potosky et al., 1995). An
issue of screening programs that has also been established in
other types of cancers (e.g., breast cancer) is over-diagnosis.
To avoid overtreatment, patients diagnosed with low-grade
PCa are commonly advised to join active surveillance (AS)
programs. In order to delay serious treatments such as
surgery, chemotherapy, or radiotherapy, in AS PCa progres-
sion is routinely examined via serum prostate-speciﬁc antigen
(PSA) levels, digital rectal examination, medical imaging,
and biopsy etc.
Biopsies are the most painful, prone to medical compli-
cations (Loeb et al., 2013) and yet also the most reliable
PCa progression examination technique used in AS. When a
patient’s biopsy Gleason grading becomes larger than 6 (Glea-
son reclassiﬁcation or GR), he is advised to switch from AS
to active treatment (Bokhorst et al., 2015). Hence the timing
of biopsies has signiﬁcant medical implications. The world’s
largest AS program, Prostate Cancer Research International
Active Surveillance (PRIAS) conducts biopsies at year 1, 4, 7,
and 10 of follow-up, and every 5 years thereafter. However, it
switches to a more frequent, annual biopsy schedule for faster-
progressing patients. These are patients with PSA doubling
time (PSA-DT) between 0 and 10 years, which is measured as
the inverse of the slope of the regression line through the base
two logarithm of PSA values. In contrast, many AS programs
use annual schedule for all patients (Tosoian et al., 2011;
Welty et al., 2015). Consequently, for slowly-progressing PCa
patients many unnecessary biopsies are scheduled. Further-
more, patients may not always comply with such schedules
(Bokhorst et al., 2015), which can lead to delayed detection
of PCa and reduce the eﬀectiveness of AS.
This article is motivated by the need to reduce the med-
ical burden of repeat biopsies while simultaneously avoiding
late detection of PCa progression. To this end, we intend to
develop personalized schedules for biopsies using historical
PSA measurements and biopsy results of patients. Person-
alized schedules for screening have received much interest in
the literature, especially in the medical decision making con-
text. For example, Markov decision process (MDP) models
have been used to create personalized screening schedules for
diabetic retinopathy (Bebu and Lachin, 2017), breast cancer
(Ayer et al., 2012), cervical cancer (Akhavan-Tabatabaei et
al., 2017), and colorectal cancer (Erenay et al., 2014). Another
type of model called joint model for time-to-event and longi-
tudinal data (Tsiatis and Davidian, 2004; Rizopoulos, 2012)
has also been used to create personalized schedules for the
measurement of longitudinal biomarkers (Rizopoulos et al.,
2016). In the context of PCa, Zhang et al. (2012) have used
partially observable MDP models to personalize the decision
of (not) deferring a biopsy to the next check-up time during
the screening process. This decision is based on the baseline
characteristics as well as a discretized PSA level of the patient
at the current check-up time.
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In comparison to the work referenced above, the schedules
we propose in this article account for the latent between-
patient heterogeneity. We achieve this by using joint models,
which are inherently patient-speciﬁc because they utilize ran-
dom eﬀects. Secondly, joint models allow a continuous time
scale and utilize the entire history of PSA levels. Lastly,
instead of making a binary decision of (not) deferring a biopsy
to the next pre-scheduled check-up time, we schedule biop-
sies at a per-patient optimal future time. To this end, using
joint models we ﬁrst obtain a full speciﬁcation of the joint
distribution of PSA levels and time of GR. We then use it
to deﬁne a patient-speciﬁc posterior predictive distribution of
the time of GR, given the observed PSA measurements and
repeat biopsies up to the current check-up time. Using the
general framework of Bayesian decision theory, we propose a
set of loss functions which are minimized to ﬁnd the optimal
time of conducting a biopsy. These loss functions yield us two
categories of personalized schedules, those based on expected
time of GR and those based on the risk of GR. In addition,
we analyze an approach where the two types of schedules are
combined. We also present methods to evaluate and compare
the various schedules for biopsies.
The rest of the article is organized as follows. Section 2
brieﬂy covers the joint modeling framework. Section 3 details
the personalized scheduling approaches we have proposed in
this article. In Section 4, we discuss methods for evaluation
and selection of a schedule. In Section 5, we demonstrate the
personalized schedules by employing them for the patients
from the PRIAS program. Lastly, in Section 6, we present
the results of a simulation study we conducted to compare
personalized schedules with PRIAS and annual schedule.
2. Joint Model for Time-to-Event and
Longitudinal Outcomes
We start with a short introduction of the joint modeling
framework we will use in our following developments. Let T ∗i
denote the true GR time for the i-th patient and let S be the
schedule of his biopsies. Let the vector of the time of biopsies
be denoted by T Si = {T Si0, T Si1, . . . , T SiNS
i
; T Sij < T
S
ik,∀j < k}, where
NSi are the total number of biopsies conducted. Because biopsy
schedules are periodical, T ∗i cannot be observed directly and
it is only known to fall in an interval li < T
∗
i ≤ ri, where
li = T SiNS
i
−1, ri = T SiNS
i
if GR is observed, and li = T SiNS
i
, ri = ∞ if
GR is not observed yet. Further let yi denote the ni × 1 vector
of PSA levels for the i-th patient. For a sample of n patients
the observed data is denoted by Dn = {li, ri, yi; i = 1, . . . , n}.
The longitudinal outcome of interest, namely PSA level, is
continuous in nature and thus to model it the joint model
utilizes a linear mixed eﬀects model (LMM) of the form:
yi(t) = mi(t) + εi(t)
= xTi (t)β + zTi (t)bi + εi(t),
where xi(t) and zi(t) denote the row vectors of the design
matrix for ﬁxed and random eﬀects, respectively. The ﬁxed
and random eﬀects are denoted by β and bi, respectively.
The random eﬀects are assumed to be normally distributed
with mean zero and q × q covariance matrix D. The true and
unobserved, error free PSA level at time t is denoted by
mi(t). The error εi(t) is assumed to be t-distributed with three
degrees of freedom and scale σ (see Web Appendix C.1), and
is independent of the random eﬀects bi.
To model the eﬀect of PSA on hazard of GR, joint mod-
els utilize a relative risk sub-model. The hazard of GR for
patient i at any time point t, denoted by hi(t), depends on a
function of subject speciﬁc linear predictor mi(t) and/or the
random eﬀects:
hi(t |Mi(t),wi)= lim
t→0
Pr
{
t ≤ T ∗i < t + t | T ∗i ≥ t,Mi(t),wi
}
t
= h0(t) exp
[
γTwi + f {Mi(t), bi,α}
]
, t > 0,
where Mi(t) = {mi(v), 0 ≤ v ≤ t} denotes the history of the
underlying PSA levels up to time t. The vector of baseline
covariates is denoted by wi, and γ are the corresponding
parameters. The function f (·) parametrized by vector α
speciﬁes the functional form of PSA levels (Brown, 2009;
Rizopoulos, 2012; Taylor et al., 2013; Rizopoulos et al., 2014)
that is used in the linear predictor of the relative risk model.
Some functional forms relevant to the problem at hand are
the following:
{
f {Mi(t), bi,α} = αmi(t),
f {Mi(t), bi,α} = α1mi(t) + α2m′i(t), with m′i(t) = dmi(t)dt .
These formulations of f (·) postulate that the hazard of GR
at time t may be associated with the underlying level mi(t) of
the PSA at t, or with both the level and velocity m′i(t) of the
PSA at t. Lastly, h0(t) is the baseline hazard at time t, and
is modeled ﬂexibly using P-splines. The detailed speciﬁcation
of the baseline hazard, and parameter estimation using the
Bayesian approach are presented in Web Appendix A of the
supplementary material.
3. Personalized Schedules for Repeat Biopsies
We intend to use the joint model ﬁtted to Dn, to create per-
sonalized schedules of biopsies. To this end, let us assume
that a schedule is to be created for a new patient j, who
is not present in Dn. Let t be the time of his latest biopsy,
and Yj(s) denote his historical PSA measurements up to
time s. The goal is to ﬁnd the optimal time u > max(t, s) of
the next biopsy.
3.1. Posterior Predictive Distribution for Time to GR
The information from Yj(s) and repeat biopsies is mani-
fested by the posterior predictive distribution g(T ∗j ), given by
(baseline covariates wi are not shown for brevity hereafter):
g(T ∗j ) = p
{
T ∗j | T ∗j > t,Yj(s),Dn
}
=
∫
p
{
T ∗j | T ∗j > t,Yj(s), θ
}
p
(
θ | Dn
)
dθ
=
∫ ∫
p
(
T ∗j | T ∗j > t, bj, θ
)
p
{
bj | T ∗j > t,Yj(s), θ
}
p
(
θ | Dn
)
dbjdθ.
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The distribution g(T ∗j ) depends on Yj(s) and Dn via the
posterior distribution of random eﬀects bj and posterior dis-
tribution of the vector of all parameters θ, respectively.
3.2. Loss Functions
To ﬁnd the time u of the next biopsy, we use principles from
statistical decision theory in a Bayesian setting (Berger, 1985;
Robert, 2007). More speciﬁcally, we propose to choose u by
minimizing the posterior expected loss Eg
{
L(T ∗j , u)
}
, where
the expectation is taken with respect to g(T ∗j ). The former is
given by:
Eg
{
L(T ∗j , u)
} = ∫ ∞
t
L(T ∗j , u)p
{
T ∗j | T ∗j > t,Yj(s),Dn
}
dT ∗j .
Various loss functions L(T ∗j , u) have been proposed in
literature (Robert, 2007). The ones we utilize, and the cor-
responding motivations are presented next.
Given the burden of biopsies, ideally only one biopsy
performed at the exact time of GR is suﬃcient. Hence, nei-
ther a time which overshoots the true GR time T ∗j , nor a
time which undershoots it, is preferred. In this regard, the
squared loss function L(T ∗j , u) = (T ∗j − u)2 and the absolute
loss function L(T ∗j , u) =
∣∣T ∗j − u∣∣ have the properties that the
posterior expected loss is symmetric on both sides of T ∗j .
Secondly, both loss functions have well known solutions avail-
able. The posterior expected loss for the squared loss function
is given by:
Eg
{
L(T ∗j , u)
} = Eg{(T ∗j − u)2}
= Eg
{
(T ∗j )
2
}+ u2 − 2uEg(T ∗j ). (1)
The posterior expected loss in (1) attains its minimum at
u = Eg(T ∗j ), that is, the expected time of GR. The posterior
expected loss for the absolute loss function is given by:
Eg
{
L(T ∗j , u)
} = Eg( ∣∣T ∗j − u∣∣ )
=
∫ ∞
u
(T ∗j − u)g(T ∗j )dT ∗j +
∫ u
t
(u − T ∗j )g(T ∗j )dT ∗j .
(2)
The posterior expected loss in (2) attains its minimum
at u = mediang(T ∗j ), that is, the median time of GR. It
can also be expressed as π−1j (0.5 | t, s), where π−1j (·) is the
inverse of dynamic survival probability πj(u | t, s) of patient j
(Rizopoulos, 2011). It is given by:
πj(u | t, s) = Pr
{
T ∗j ≥ u | T ∗j > t,Yj(s),Dn
}
, u ≥ t.
Even though Eg(T
∗
j ) or mediang(T
∗
j ) may be obvious choices
from a statistical perspective, from the viewpoint of doctors
or patients, it could be more intuitive to make the decision
for the next biopsy by placing a cutoﬀ 1 − κ, where 0 ≤ κ ≤ 1,
on the dynamic incidence/risk of GR. This approach would
be successful if κ can suﬃciently well diﬀerentiate between
patients who will obtain GR in a given period of time versus
others. This approach is also useful when patients are appre-
hensive about delaying biopsies beyond a certain risk cutoﬀ.
Thus, a biopsy can be scheduled at a time point u such that
the dynamic risk of GR is higher than a certain threshold
1 − κ, beyond u. To this end, the posterior expected loss for
the following multilinear loss function can be minimized to
ﬁnd the optimal u:
Lk1,k2(T
∗
j , u) =
{
k2(T
∗
j − u), k2 > 0 if T ∗j > u,
k1(u − T ∗j ), k1 > 0 otherwise,
where k1, k2 are constants parameterizing the loss function.
The posterior expected loss Eg
{
Lk1,k2(T
∗
j , u)
}
obtains its
minimum at u = π−1j
{
k1/(k1 + k2) | t, s
}
(Robert, 2007). The
choice of the two constants k1 and k2 is equivalent to the choice
of κ = k1/(k1 + k2).
In practice, for some patients, we may not have suﬃcient
information to accurately estimate their PSA proﬁle. The
resulting high variance of g(T ∗j ) could lead to a mean (or
median) time of GR which overshoots the true T ∗j by a big
margin. In such cases, the approach based on the dynamic
risk of GR with smaller risk thresholds is more risk-averse
and thus could be more robust to large overshooting margins.
This consideration leads us to a hybrid approach, namely, to
select u using dynamic risk of GR-based approach when the
spread of g(T ∗j ) is large, while using Eg(T
∗
j ) or mediang(T
∗
j )
when the spread of g(T ∗j ) is small. What constitutes a large
spread will be application-speciﬁc. In PRIAS, within the ﬁrst
10 years, the maximum possible delay in detection of GR is
3 years. Thus, we propose that if the diﬀerence between the
0.025 quantile of g(T ∗j ), and Eg(T
∗
j ) or mediang(T
∗
j ) is more
than 3 years then proposals based on the dynamic risk of GR
be used instead.
3.3. Estimation
Since there is no closed form solution available for Eg(T
∗
j ), for
its estimation we utilize the following relationship between
Eg(T
∗
j ) and πj(u | t, s):
Eg(T
∗
j ) = t +
∫ ∞
t
πj(u | t, s)du. (3)
However, as mentioned earlier, selection of the optimal biopsy
time based on Eg(T
∗
j ) alone will not be practically useful when
the varg(T
∗
j ) is large, which is given by:
varg(T
∗
j ) = 2
∫ ∞
t
(u − t)πj(u | t, s)du −
{∫ ∞
t
πj(u | t, s)du
}2
.
(4)
Since there is no closed form solution available for the
integrals in (3) and (4), we approximate them using Gauss-
Kronrod quadrature (see Web Appendix B). The variance
depends both on the last biopsy time t and the PSA history
Yj(s), as demonstrated in Section 5.2.
For schedules based on dynamic risk of GR, the choice
of threshold κ has important consequences because it dic-
tates the timing of biopsies. Often it may depend on the
amount of risk that is acceptable to the patient (if maximum
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acceptable risk is 5%, κ = 0.95). When κ cannot be chosen
on the basis of the input of the patients, we propose to
automate its choice. More speciﬁcally, given the time t of
latest biopsy we propose to choose a κ for which a binary
classiﬁcation accuracy measure (Lo´pez-Rato´n et al., 2014),
discriminating between cases (patients who experience GR)
and controls, is maximized. In joint models, a patient j is
predicted to be a case in the time window t if πj(t + t |
t, s) ≤ κ, or a control if πj(t + t | t, s) > κ (Rizopoulos, 2016;
Rizopoulos et al., 2017). We choose t to be 1 year. This
is because, in AS programs at any point in time, it is of
interest to identify and provide extra attention to patients
who may obtain GR in the next 1 year. As for the choice
of the binary classiﬁcation accuracy measure, we chose F1
score since it is in line with our goal to focus on potential
cases in time window t. The F1 score combines both sen-
sitivity and positive predictive value (PPV) and is deﬁned
as:
F1(t, t, s, κ) = 2 TPR(t, t, s, κ) PPV(t, t, s, κ)
TPR(t, t, s, κ) + PPV(t, t, s, κ) ,
TPR(t, t, s, κ) = Pr{πj(t + t | t, s) ≤ κ | t < T ∗j ≤ t + t},
PPV(t, t, s, κ) = Pr{t < T ∗j ≤ t + t | πj(t + t | t, s) ≤ κ},
where TPR(·) and PPV(·) denote time dependent true posi-
tive rate (sensitivity) and positive predictive value (precision),
respectively. The estimation for both is similar to the estima-
tion of AUC(t, t, s) given by Rizopoulos et al. (2017). Since
a high F1 score is desired, the corresponding value of κ is
argmaxκ F1(t, t, s, κ). We compute the latter using a grid
search approach. That is, ﬁrst the F1 score is computed using
the available dataset over a ﬁne grid of κ values between 0
and 1, and then κ corresponding to the highest F1 score is
chosen. Furthermore, in this article we use κ chosen only on
the basis of the F1 score.
3.4. Algorithm
When a biopsy gets scheduled at a time u < T ∗j , then GR is
not detected at u and at least one more biopsy is required
at an optimal time unew > max(u, s). This process is repeated
until GR is detected. To aid in medical decision making, we
elucidate this process via an algorithm in Figure 1. AS pro-
grams strongly advise that two biopsies have a gap of at least
1 year. Thus, when u − t < 1, the algorithm postpones u to
t + 1, because it is the time nearest to u, at which the 1-year
gap condition is satisﬁed.
4. Evaluation of Schedules
In order to compare various schedules of biopsies, we require
measures of their eﬃcacy. We propose to use two measures,
namely the number of biopsies (burden) NSj ≥ 1 a schedule
S conducts for the j-th patient to detect GR, and the oﬀset
OSj ≥ 0 by which it overshoots T ∗j . The oﬀset OSj is deﬁned as
OSj = T SjNS
j
− T ∗j , where T SjNS
j
≥ T ∗j is the time at which GR is
detected. Our interest lies in the joint distribution p(NSj ,O
S
j )
of the number of biopsies and the oﬀset. The least burdensome
scenario is when NSj = 1 and OS = 0. Hence, realistically we
should select a schedule with a low mean number of biopsies
E(NSj ) as well a low mean oﬀset E(O
S
j ). It is also desired that
a schedule has a low variance for both the number of biop-
sies var(NSj ), and oﬀset var(O
S
j ), so that the schedule works
similarly for most patients.
4.1. Choosing a Schedule
Given the multiple schedules of biopsies, it is of clinical
interest to choose a suitable schedule. Using principles from
compound optimal designs (La¨uter, 1976), we propose to
choose a schedule S which minimizes a loss function of the
following form:
L(S) =
R∑
r=1
ηrRr(NSj ), (5)
where Rr(·) is a function of either NSj or OSj (for brevity, only
NSj is used in the equation above). Some examples of Rr(·)
are mean, median, variance, and quantile function. Constants
η1, . . . , ηR, where 0 ≤ ηr ≤ 1 and
∑R
r=1 ηr = 1, are weights
to diﬀerentially weigh-in the contribution of each of the
R criteria. An example loss function is:
L(S) = η1E(NSj ) + η2E(OSj ). (6)
The choice of η1 and η2 is not easy, because the burden of a
biopsy cannot be compared to a unit increase in oﬀset eas-
ily. To obviate this problem we utilize the equivalence between
compound and constrained optimal designs (Cook and Wong,
1994). More speciﬁcally, it can be shown that for any η1 and
η2 there exists a constant C > 0 for which minimization of
the loss function in (6) is equivalent to minimization of the
loss function subject to the constraint that E(NSj ) < C. That
is, a schedule which conducts at most C biopsies on aver-
age and detects GR earliest should be chosen. The choice
of C could be based on the number of biopsies a patient is
willing to undergo. In the more generic case in (5), a sched-
ule can be chosen by minimizing RR(·) under the constraint
Rr(·) < Cr; r = 1, . . . , R − 1.
5. Demonstration of Personalized Schedules
To demonstrate the personalized schedules, we apply them to
the patients enrolled in PRIAS study. To this end, we divide
the PRIAS dataset into a training part (5264 patients) and
a demonstration part (three patients). We ﬁt a joint model
to the training dataset and then use it to create schedules
for the demonstration patients. We ﬁt the joint model using
the R package JMbayes (Rizopoulos, 2016), which uses the
Bayesian approach for parameter estimation.
5.1. Fitting the Joint Model to the PRIAS Dataset
For each of the PRIAS patients, we know their age at the
time of inclusion in AS, PSA history, and the time interval in
which GR is detected. For the longitudinal analysis of PSA
we use log2(PSA + 1) measurements instead of the raw data
(Pearson et al., 1994; Lin et al., 2000). The longitudinal
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Figure 1. Algorithm for creating a personalized schedule for patient j. The time of the latest biopsy is denoted by t. The
time of the latest available PSA measurement is denoted by s. The proposed personalized time of biopsy is denoted by u. The
time at which a repeat biopsy was proposed on the last visit to the hospital is denoted by upv. The time of the next visit for
the measurement of PSA is denoted by snv. This ﬁgure appears in color in the electronic version of this article.
sub-model of the joint model we ﬁt is given by:
log2(PSAi + 1)(t) = β0 + β1(Agei − 70) + β2(Agei − 70)2
+
4∑
k=1
βk+2Bk(t,K) + bi0 + bi1B7(t, 0.1)
+bi2B8(t, 0.1) + εi(t), (7)
where Bk(t,K) denotes the k-th basis function of a B-spline
with three internal knots at K = {0.1, 0.5, 4} years, and bound-
ary knots at 0 and 7 (0.99 quantile of the observed follow-up
times) years. The spline for the random eﬀects consists of one
internal knot at 0.1 years and boundary knots at 0 and 7
years. For the relative risk sub-model the hazard function we
ﬁt is given by:
hi(t) = h0(t) exp
{
γ1(Agei − 70) + γ2(Agei − 70)2
+α1mi(t) + α2m′i(t)
}
, (8)
where α1 and α2 are measures of strength of the association
between hazard of GR and log2(PSAi + 1) value mi(t) and
log2(PSAi + 1) velocity m′i(t), respectively.
From the ﬁtted joint model we found that log2(PSA + 1)
velocity and the age at the time of inclusion in AS were
157
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signiﬁcantly associated with the hazard of GR. For any
patient, an increase in log2(PSA + 1) velocity from −0.06 to
0.14 (ﬁrst and third quartiles of the ﬁtted velocities, respec-
tively) corresponds to a 2.05 fold increase in the hazard of
GR. In terms of the predictive performance, we found that
the area under the receiver operating characteristic curves
(Rizopoulos et al., 2017) was 0.61, 0.65, and 0.59 at years 1,
2, and 3 of follow-up, respectively. Parameter estimates are
presented in detail in Web Appendix C.
In PRIAS, the interval li < T
∗
i ≤ ri in which GR is detected
depends on the PSA-DT of the patient. However, because
the parameters are estimated using a full likelihood approach
(Tsiatis and Davidian, 2004), the joint model gives valid esti-
mates for all of the parameters, under the condition that the
model is correctly speciﬁed (see Web Appendix A.2 and C.3).
To this end, we performed several sensitivity analysis in our
model (e.g., changing the position of the knots, etc.) to investi-
gate the ﬁt of the model and also the robustness of the results.
In all of our attempts, the same conclusions were reached,
namely that the velocity of the longitudinal outcome is more
strongly associated with the hazard of GR than the value.
5.2. Personalized Schedules for the First Demonstration
Patient
We now demonstrate the functioning of the personal-
ized schedules for the ﬁrst demonstration patient (see
Web Appendix D for the other two demonstration
patients). The ﬁtted and observed log2(PSA + 1) pro-
ﬁle, time of latest biopsy, and proposed biopsy times
u for him are shown in the top panel of Figure 2.
We can see that with a consistently decreasing PSA and neg-
ative repeat biopsy between year 3 and 4.5, the proposed time
of biopsy based on the dynamic risk of GR has increased from
3.05 years (κ = 0.94) to 14.73 years (κ = 0.96) in this period.
The proposed time of biopsy based on expected time of GR
has also increased from 14.40 to 15.97 years. We can also
see in the bottom panel of Figure 2 that after each negative
repeat biopsy, SD[T ∗j ] =
√
varg(T
∗
j ) decreases sharply. Thus,
if the expected time of GR-based approach is used, then the
oﬀset OSj will be smaller on average for biopsies scheduled
after the second repeat biopsy than those scheduled after the
ﬁrst repeat biopsy.
6. Simulation Study
In Section 5.2, we demonstrated that the personalized sched-
ules, schedule future biopsies according to the historical
data of each patient. However, we could not perform a
full-scale comparison between personalized and PRIAS sched-
ules, because the true time of GR was not known for the
PRIAS patients. To this end, we conducted a simulation study
comparing personalized schedules with PRIAS and annual
schedule, whose details are presented next.
6.1. Simulation Setup
The population of AS patients in this simulation study is
assumed to have the same entrance criteria as that of PRIAS.
The PSA and hazard of GR for these patients follow a joint
model of the form postulated in Section 5.1, with the only
change that log2 PSA levels are used as the outcome. The
population joint model parameters are equal to the posterior
Figure 2. Top panel: ﬁtted versus observed log2(PSA + 1)
proﬁle, history of repeat biopsies, and corresponding person-
alized schedules for the ﬁrst demonstration patient. Bottom
panel: history of repeat biopsies and standard deviation
SDg(T
∗
j ) =
√
varg(T
∗
j ) of the posterior predictive distribution
of time of GR over time for the ﬁrst demonstration patient.
mean of parameters estimated from the corresponding joint
model ﬁtted to the PRIAS dataset. We intend to test the eﬃ-
cacy of diﬀerent schedules for a population which has patients
with both faster as well as slowly-progressing PCa. This rate
of progression is not only manifested via PSA proﬁles but also
via the baseline hazard. We assume that there are three equal
sized subgroups G1, G2, and G3 of patients in the popula-
tion, each with a baseline hazard from a Weibull distribution,
with the following shape and scale parameters (k, λ): (1.5, 4),
(3, 5), and (4.5, 6) for G1,G2, and G3, respectively. The eﬀect
of these parameters is that the mean GR time is lowest in G1
(fast PCa progression) and highest in G3 (slow PCa progres-
sion).
From this population, we have sampled 500 datasets with
1000 patients each. We generate a true GR time for each of
the patients, and then sample a set of PSA measurements
at the same time points as given in PRIAS protocol (see
Web Appendix C). We then split the dataset into a training
(750 patients) and a test (250 patients) part, and generate a
random and non-informative censoring time for the training
patients. We next ﬁt a joint model of the speciﬁcation given
in (7) and (8) to each of the 500 training datasets and obtain
MCMC samples from the 500 sets of the posterior distribution
of the parameters. Using these ﬁtted joint models, we obtain
the posterior predictive distribution of time of GR for each of
the 500 × 250 test patients. This distribution is further used
to create personalized biopsy schedules for the test patients.
For every test patient we conduct hypothetical biopsies using
the following six types of schedules (abbreviated names in
parenthesis): personalized schedules based on expected time
of GR (Exp. GR time) and median time of GR (Med. GR
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time), personalized schedules based on dynamic risk of GR
(Dyn. risk GR), a hybrid approach between median time of
GR and dynamic risk of GR (Hybrid), PRIAS schedule and
the annual schedule. The biopsies are conducted as per the
algorithm in Figure 1.
To compare the aforementioned schedules we require esti-
mates of the various measures of eﬃcacy described in
Section 4. To this end, for schedule S, we compute pooled
estimates of mean oﬀset E(OSj ) and variance of oﬀset var(O
S
j ),
as below (estimates for NSj are similar):
̂E(OSj ) =
∑500
k=1 nk
̂E(OSk )∑500
k=1 nk
,
̂var(OSj ) =
∑500
k=1(nk − 1)̂var(OSk )∑500
k=1(nk − 1)
,
where nk denotes the number of test patients,
̂E(OSk ) =∑nk
l=1 O
S
kl/nk is the estimated mean and
̂var(OSk ) =∑nk
l=1
{
OSkl −̂E(OSk )
}2
/(nk − 1) is the estimated variance of
the oﬀset for the k-th simulation. The oﬀset for the l-th test
patient of the k-th dataset is denoted by OSkl.
6.2. Results
The pooled estimates of the aforementioned measures are
summarized in Table 1. In addition, estimated values of E(OSj )
are plotted against E(NSj ) in Figure 3. The ﬁgure shows that
across the schedules there is an inverse relationship between
number E(OSj ) and E(N
S
j ). For example, the annual sched-
ule conducts on average 5.2 biopsies to detect GR, which is
the highest among all schedules. However, it has the least
average oﬀset of 6 months as well. On the other hand, the
schedule based on expected time of GR conducts only 1.9
biopsies on average to detect GR, the least among all sched-
ules, but it also has the highest average oﬀset of 15 months
(similar for median time of GR). Since the annual schedule
attempts to contain the oﬀset within a year it has the least
SD(OSj ) =
√
var(OSj ) (Figure 5). However, to achieve this, it
conducts a wide range of number of biopsies from patient to
patient, i.e., highest SD(NSj ) =
√
var(NSj ) (Figure 4). In this
regard, schedules based on expected and median time of GR
perform the opposite of annual schedule.
The PRIAS schedule conducts only 0.3 biopsies less than
the annual schedule, but with a higher SD(OSj ), early detec-
tion is not always guaranteed. In comparison, the dynamic
risk of GR-based schedule performs slightly better than the
PRIAS schedule in all four criteria. The hybrid approach com-
bines the beneﬁts of methods with low E(NSj ) and SD(N
S
j ),
and methods with low E(OSj ) and SD(O
S
j ). It conducts 1.5
biopsies less than the annual schedule on average and with
a E(OSj ) of 9.7 months it detects GR within a year since
its occurrence. Moreover, it has both SD(NSj ) and SD(O
S
j )
comparable to PRIAS.
The performance of each schedule diﬀers for the three
subgroups G1,G2, and G3. The annual schedule remains
the most consistent across subgroups in terms of the oﬀ-
set, but it conducts two extra biopsies for the subgroup
G3 (slowly-progressing PCa) than G1 (faster-progressing
Table 1
Estimated mean and standard deviation (SD), of the number
of biopsies NSj conducted until Gleason reclassiﬁcation (GR)
is detected, and of the oﬀset OSj (diﬀerence in time at which
GR is detected and the true time of GR, in months), for the
simulated (500 datasets) test patients, across diﬀerent
schedules and subgroups. Patients in subgroup G1 have the
fastest prostate cancer progression rate, whereas patients in
subgroup G3 have the slowest progression rate. Types of
personalized schedules (full names in brackets): Exp. GR
time (expected time of GR), Med. GR time (median time of
GR), Dyn. risk GR (schedules based on dynamic risk of
GR), hybrid (a hybrid approach between median time of GR
and dynamic risk of GR). Annual corresponds to a schedule
of yearly biopsies and PRIAS corresponds to biopsies as per
PRIAS protocol.
a) All hypothetical subgroups
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 5.24 6.01 2.53 3.46
PRIAS 4.90 7.71 2.36 6.31
Dyn. risk GR 4.69 6.66 2.19 4.38
Hybrid 3.75 9.70 1.71 7.25
Med. GR time 2.06 13.88 1.41 11.80
Exp. GR time 1.92 15.08 1.19 12.11
b) Hypothetical subgroup G1
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 4.32 6.02 3.13 3.44
PRIAS 4.07 7.44 2.88 6.11
Dyn. risk GR 3.85 6.75 2.69 4.44
Hybrid 3.25 10.25 2.16 8.07
Med. GR time 1.84 20.66 1.76 14.62
Exp. GR time 1.72 21.65 1.47 14.75
c) Hypothetical subgroup G2
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 5.18 5.98 2.13 3.47
PRIAS 4.85 7.70 2.00 6.29
Dyn. risk GR 4.63 6.66 1.82 4.37
Hybrid 3.68 10.32 1.37 7.45
Med. GR time 1.89 12.33 1.16 9.44
Exp. GR time 1.77 13.54 0.98 9.83
d) Hypothetical subgroup G3
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 6.20 6.02 1.76 3.46
PRIAS 5.76 7.98 1.71 6.51
Dyn. risk GR 5.58 6.58 1.56 4.33
Hybrid 4.32 8.55 1.26 5.91
Med. GR time 2.45 8.70 1.15 6.32
Exp. GR time 2.27 10.09 0.99 7.47
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Figure 3. Estimated mean number of biopsies conducted
until Gleason reclassiﬁcation (GR) is detected, and mean oﬀ-
set (diﬀerence in time at which GR is detected and the true
time of GR, in months) for the simulated (500 datasets)
test patients, across diﬀerent schedules. Types of person-
alized schedules (full names in brackets): Exp. GR time
(expected time of GR), Med. GR time (median time of GR),
Dyn. risk GR (schedules based on dynamic risk of GR),
hybrid (a hybrid approach between median time of GR and
dynamic risk of GR). Annual corresponds to a schedule of
yearly biopsies and PRIAS corresponds to biopsies as per
PRIAS protocol.
PCa). The performance of schedule based on expected
time of GR is the most consistent in terms of the num-
ber of biopsies but it detects GR a year later on average
in subgroup G1 than G3. For the dynamic risk of GR-
based schedule and the hybrid schedule, the dynamics are
similar to that of the annual schedule. Unlike the lat-
ter two schedules, the PRIAS schedule not only conducts
more biopsies in G3 than G1 but also detects GR later
in G3 than G1.
Figure 4. Boxplot showing variation in number of biopsies
conducted by various biopsy schedules for the simulated (500
datasets) test patients. Biopsies are conducted until Gleason
reclassiﬁcation (GR) is detected. Types of personalized sched-
ules (full names in brackets): Exp. GR Time (expected time
of GR), Med. GR time (median time of GR), Dyn. risk GR
(schedules based on dynamic risk of GR), hybrid (a hybrid
approach between median time of GR and dynamic risk of
GR). Annual corresponds to a schedule of yearly biopsies and
PRIAS corresponds to biopsies as per PRIAS protocol.
Figure 5. Boxplot showing variation in biopsy oﬀset (dif-
ference in time at which Gleason reclassiﬁcation, also known
as GR, is detected and the true time of GR, in months) for the
simulated (500 datasets) test patients, across diﬀerent sched-
ules. Types of personalized schedules (full names in brackets):
Exp. GR time (expected time of GR), Med. GR time (median
time of GR), Dyn. risk GR (schedules based on dynamic risk
of GR), hybrid (a hybrid approach between median time of
GR and dynamic risk of GR). Annual corresponds to a sched-
ule of yearly biopsies and PRIAS corresponds to biopsies as
per PRIAS protocol.
The choice of a suitable schedule using (5) depends on the
chosen measure for evaluation of schedules. In this regard,
the schedules we compared either have high SD(OSj ) and low
SD(NSj ), or vice versa (Table 1). Thus, applying a cutoﬀ on
E(OSj ) when SD(O
S
j ) is high may not be as fruitful (same for
NSj ) as applying a cutoﬀ on SD(O
S
j ) or quantile(s) of O
S
j . For
example, the schedule based on the dynamic risk of GR is
suitable if on average the least number of biopsies are to be
conducted to detect GR, while simultaneously making sure
that at least 90% of the patients have an average oﬀset less
than 1 year.
7. Discussion
In this article, we presented personalized schedules based
on joint models for time-to-event and longitudinal data, for
surveillance of PCa patients. These schedules are dynamic in
nature, and at any given follow-up time, utilize a patient’s
historical PSA measurements and repeat biopsies conducted
up to that time. We proposed two types of personalized sched-
ules, namely those based on expected and median time of GR
of a patient, and those based on the dynamic risk of GR. We
also proposed a combination (hybrid approach) of these two
approaches, which is useful in scenarios where the variance of
time of GR for a patient is high. We then proposed criteria
for evaluation of various schedules and a method to select a
suitable schedule.
We demonstrated the dynamic and personalized nature of
our schedules using the PRIAS dataset. We observed that
a recent biopsy impacts the schedules more than recent PSA
measurements, which correlates with biopsies being more reli-
able. Since true GR time is not known for PRIAS patients,
we conducted a simulation study to compare personalized
schedules with PRIAS and annual schedules. The latter two
schedules are already in practice. Hence, it can be argued
that the maximum possible oﬀsets due to these schedules
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(1 and 3 years, respectively) are acceptable to doctors. Thus,
less frequent schedules with oﬀset under 1 year may reduce
the burden of biopsies while simultaneously being practical.
For example, for slowly-progressing patients in our simula-
tion study, we observed that the schedule based on expected
time of GR conducts on average two biopsies and has an
average oﬀset of 10 months. In comparison, annual schedule
conducts six biopsies on average and gives an oﬀset smaller by
only 4 months, making the personalized schedule a suitable
alternative. For high-risk patients, however, early detection
(annual or PRIAS schedule) may be necessary, given the
rapidness of progression. When it is not known in advance
if a patient will have a fast or slow-progression of PCa, the
hybrid approach may be used. It conducts one biopsy less than
the annual schedule in faster-progressing PCa patients and
has an average oﬀset of 10.25 months. For slowly-progressing
PCa patients it conducts two biopsies less than the annual
schedule and has an average oﬀset of 8.55 months.
More personalized schedules can be added to the current
set, using loss functions which asymmetrically penalize over-
shooting/undershooting the target GR time. For dynamic risk
of GR-based schedules, more simulations are required to com-
pare data-driven κ values (e.g., F1 score), with κ chosen using
decision analytic approaches such as the net beneﬁt measure
(Vickers and Elkin, 2006), and with various ﬁxed κ values
used by doctors in practice. In general, the Gleason scores are
susceptible to inter-observer variation (Carlson et al., 1998).
Schedules which account for error in the measurement of time
of GR will be interesting to investigate further (Coley et al.,
2017). Lastly, there is potential for including diagnostic infor-
mation from magnetic resonance imaging (MRI) or DRE.
When such information is not continuous in nature, our pro-
posed methodology can be easily extended by utilizing the
framework of generalized linear mixed models.
8. Supplementary Materials
Web Appendix A, B, and C, D referenced in Sections 2, 3.3,
and 5, respectively, and the R code for ﬁtting the joint model
to the PRIAS dataset, and for the simulation study are avail-
able with this article at the Biometrics website on Wiley
Online Library.
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